Peer-influenced content. Sources you trust. No registration required. This is HCN.

Annals of Internal MedicineOutpatient Treatment of Confirmed COVID-19

Some of the key findings of this meta-analysis of antiviral therapy in the outpatient setting include: (treatment vs no-treatment)

  • Probable reduction of hospitalization with Nirmatrelvir–ritonavir and casirivimab–imdevimab (1% vs 6%)
  • Probable reduction in all-cause mortality with Nirmatrelvir–ritonavir (0% vs 1%)
  • Probable improved recovery with regdanvimab (87% vs 72%)
  • Four-day reduction in time to recovery with casirivimab-imdevimab
  • Possible reduction in recovery rates with hydroxychloroquine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form